1700021F02Rik Inhibitors
Chemical inhibitors of 1700021F02Rik target various signaling pathways to achieve functional inhibition of the protein. Wortmannin and LY294002 are known to directly inhibit phosphoinositide 3-kinases (PI3K), which are upstream regulators in the signaling cascade that 1700021F02Rik is a part of. By binding irreversibly to the PI3K enzymes, Wortmannin prevents the phosphorylation of downstream targets, including Akt, which is crucial for the activation of 1700021F02Rik. Similarly, LY294002 competes with ATP for binding to the p110 subunit of PI3K, effectively blocking the kinase activity and subsequent signaling required for 1700021F02Rik function. Rapamycin and its derivative Everolimus form a complex with FKBP12 and bind to mTOR Complex 1 (mTORC1), a key downstream element in the pathway involving 1700021F02Rik. The inhibition of mTORC1 by these complexes leads to a disruption in the signaling process essential for the proper functioning of 1700021F02Rik.
Other inhibitors, such as PP242, Torin 1, and KU-0063794, are ATP-competitive inhibitors that target mTORC1 and mTORC2, which play a pivotal role in the pathway of 1700021F02Rik. By inhibiting both mTOR complexes, these chemicals ensure a comprehensive blockage of the mTOR signaling, which is necessary for the functional activity of 1700021F02Rik. WZ4003, although a selective inhibitor of the NUAK family, indirectly affects 1700021F02Rik by inhibiting ULK1 kinase activity, which is associated with autophagy and related signaling pathways. PF-04691502 and BGT226 are dual PI3K/mTOR inhibitors, simultaneously disrupting the signals from both kinases that are required for the activation of 1700021F02Rik. Finally, PI-103 and AZD8055 also act on PI3K and mTOR, but PI-103 has a broader target profile against various PI3K isoforms, while AZD8055 is a potent inhibitor that shuts down both mTORC1 and mTORC2, ensuring that the signaling pathways critical for the function of 1700021F02Rik are effectively inhibited. Through these mechanisms, these chemical inhibitors can alter the functional activity of 1700021F02Rik by modulating the protein's signaling environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal metabolite of fungi which acts as an irreversible inhibitor of phosphoinositide 3-kinases (PI3K), leading to the inhibition of the PI3K/Akt pathway. Since 1700021F02Rik is involved in this signaling cascade, its function can be inhibited by the prevention of Akt phosphorylation and subsequent downstream signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a synthetic molecule that inhibits PI3K by competing with ATP for binding to the p110 subunit. This inhibition deprives 1700021F02Rik of PI3K-mediated signals necessary for its activation and function, thereby functionally inhibiting 1700021F02Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12, which then binds to and inhibits mTOR Complex 1 (mTORC1). Inhibition of mTORC1 downregulates several downstream processes, which are crucial for the function of 1700021F02Rik, leading to its functional inhibition. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus, a derivative of Rapamycin, also binds to FKBP12 and inhibits mTORC1. This blocks the mTOR signaling pathway, which is necessary for the functional activity of 1700021F02Rik, thus inhibiting the protein. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is an ATP-competitive inhibitor that targets both mTORC1 and mTORC2, thereby halting the mTOR signaling pathway. Inhibition of these mTOR complexes leads to a reduction in the signals required for the functional activity of 1700021F02Rik, thereby inhibiting it. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 is a selective inhibitor of mTOR, blocking the activity of both mTORC1 and mTORC2. This inhibition leads to the disruption of the mTOR pathway, which is essential for the function of 1700021F02Rik, effectively inhibiting the protein. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ4003 is a selective inhibitor of the NUAK family, which has been shown to inhibit ULK1 kinase activity. As ULK1 is involved in autophagy and can be connected to signaling pathways that include 1700021F02Rik, the inhibition of ULK1 by WZ4003 could lead to the functional inhibition of 1700021F02Rik by disrupting its associated signaling networks. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a multi-targeted PI3K inhibitor with additional activity against mTOR. By inhibiting PI3K and mTOR, PI-103 prevents the phosphorylation and activation of downstream targets necessary for the function of 1700021F02Rik, thus inhibiting the protein. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
AZD8055 is a potent ATP-competitive inhibitor of mTOR that inhibits both mTORC1 and mTORC2. | ||||||